Magenta Therapeutics: Developing Novel Treatments In Hematopoietic Stem Cell Transplants

Akari Therapeutics shares jumped on Wednesday after the firm announced that the FDA has granted Fast Track designation for its stem cell transplant treatment......»»

Magenta Therapeutics Inc (NASDAQ: MGTA), which made an initial public offering last month, is operating in an area largely overlooked by drug developers, acco Latest Ratings for MGTA .....»»

A paper co-authored by an executive of a stem cell firm already under FDA fire has been retracted.A paper co-authored by an executive of a stem cell firm already under FDA fire has been retracted......»»

A paper co-authored by an executive of a stem cell firm already under FDA fire has been retracted. A paper co-authored by an executive of a stem cell firm already under FDA fire has been retracted......»»

A research program into stem cells and autism is attracting criticism. Experts say it is unwittingly boosting a market .....»»

Clinics with unproven stem cell treatments are already targeting COVID-19 fears. Clinics with unproven stem cell treatments are already targeting COVID-19 fears......»»

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical stage company developing treatments for rare and spec.....»»

A La Jolla clinic pitching $15,000 stem cell treatments files for bankruptcy, facing a lawsuit from former patients. A La Jolla clinic pitching $15,000 stem cell treatments files for bankruptcy, facing a lawsuit from former patients......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

SAN FRANCISCO, Aug. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and .....»»

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline......»»

SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important .....»»

Karuna Therapeutics Inc. set terms Monday for its initial public offering, in which the biopharmaceutical company developing treatments for neuropsychiatric conditions is expected to raise up to $74.4 mil.....»»

Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck & Co. Merck (NYSE: MRK) announced Monday that it has agreed to pay up.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today reported financial re.....»»

Abeona Therapeutics Inc (NASDAQ: ABEO), which employs gene and cell therapy for potential rare disease treatments, has a favorable risk-reward profile, according to Seaport Global Securities. Latest Ratings for ABEO DateF.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, aut.....»»